CV Trials For Obesity Drugs Won’t Be Conducive To Easy Interpretation, Panel Indicates
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will discuss design issues March 29 and vote on the need for pre-approval trials in drugs without a CV safety signal.